CoChat

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth

Open access
Doleschel, Dennis, Hoff, Sabine, Koletnik, Susanne, Rix, Anne, Zopf, Dieter, Kiessling, Fabian, Lederle, Wiltrud · 2021 · Journal of Experimental & Clinical Cancer Research

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Background: Patients with advanced colorectal cancer (CRC) have a poor prognosis. Combinations of immunotherapies and anti-angiogenic agents are currently being evaluated in clinical trials. In this study, the multikinase inhibitor regorafenib (REG) was combined with an anti-programmed cell death protein 1 (aPD1) antibody in syngeneic murine microsatellite-stable (MSS) CT26 and hypermutated MC38 colon cancer models to gain mechanistic insights into potential drug synergism. Methods: Growth and progression of orthotopic CT26 and subcutaneous MC38 colon cancers were studied under treatment with varying doses of REG and aPD1 alone or in combination. Sustained effects were studied after treatment discontinuation. Changes in the tumor microenvironment were assessed by dynamic contrast-enhanced MRI, and histological and molecular analyses. Results: In both models, REG and aPD1 combination therapy significantly improved anti-tumor activity compared with single agents. However, in the CT26 model, the additive benefit of aPD1 only became apparent after treatment cessation. The combination treatment efficiently prevented tumor regrowth and completely suppressed liver metastasis, whereas the anti-tumorigenic effects of REG alone were abrogated soon after drug discontinuation. During treatment, REG significantly reduced the infiltration of immunosuppressive macrophages and regulatory T (Treg) cells into the tumor microenvironment. aPD1 significantly enhanced intratumoral IFNγ levels. The drugs synergized to induce sustained M1 polarization and durable reduction of Treg cells, which can explain the sustained tumor suppression. Conclusions: This study highlights the synergistic immunomodulatory effects of REG and aPD1 combination therapy in mediating a sustained inhibition of colon cancer regrowth, strongly warranting clinical evaluation in CRC, including MSS tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13046-021-02043-0

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The combination of REG and aPD1 results in additive suppression of subcutaneous MC38 tumor growth. a Study design. b Tumor growth curves with mean tumor volumes ± SD (n = 10). c Intratumoral levels of IFNγ mRNA at study end determined by qRT-PCR. d Intratumoral levels of IFNγ protein from total tumor lysates at study end determined by enzyme-linked immunosorbent assay. Mean ± SD (n = 5) and individual values (dots) are shown. *p < 0.05; **p < 0.01; ***p < 0.001
Fig. 1 The combination of REG and aPD1 results in additive suppression of subcutaneous MC38 tumor growth. a Study design. b Tumor growth curves with mean tumor volumes ± SD (n = 10). c Intratumoral levels of IFNγ mRNA at study end determined by qRT-PCR. d Intratumoral levels of IFNγ protein from total tumor lysates at study end determined by enzyme-linked immunosorbent assay. Mean ± SD (n = 5) and individual values (dots) are shown. *p < 0.05; **p < 0.01; ***p < 0.001CC BY · PubMed Central
Fig. 2 REG and REG + aPD1 significantly inhibit tumor growth and liver metastasis in orthotopic CT26 colon tumors. a Study design. Gray arrowhead indicates imaging/sampling before first drug administration for baseline determination. b Tumor growth inhibition. Mean RTV given as a percentage of the baseline volumes ± SD (n = 6–7). c Representative images. First panel: dissected tumors; second panel: T2-weighted MR images (white arrows demarcate tumors); third panel: TUNEL staining (red) with DAPI stained nuclei (blue); fourth panel: livers with metastases depicted by white arrows. Scale bar: 10 mm (MRI and ex vivo) and 100 µm (TUNEL). d Quantification of TUNEL stainings (tumor apoptosis) from frozen tumor sections at study end with mean values ± SD (n = 5–7) and individual values (dots). Statistical significance (#day 11; *day 14): */#p < 0.05; **/##p < 0.01; ***/###p < 0.001. e Number of mice with liver metastases compared with total number of mice and percentages (number in %)
Fig. 2 REG and REG + aPD1 significantly inhibit tumor growth and liver metastasis in orthotopic CT26 colon tumors. a Study design. Gray arrowhead indicates imaging/sampling before first drug administration for baseline determination. b Tumor growth inhibition. Mean RTV given as a percentage of the baseline volumes ± SD (n = 6–7). c Representative images. First panel: dissected tumors; second panel: T2-weighted MR images (white arrows demarcate tumors); third panel: TUNEL staining (red) with DAPI stained nuclei (blue); fourth panel: livers with metastases depicted by white arrows. Scale bar: 10 mm (MRI and ex vivo) and 100 µm (TUNEL). d Quantification of TUNEL stainings (tumor apoptosis) from frozen tumor sections at study end with mean values ± SD (n = 5–7) and individual values (dots). Statistical significance (#day 11; *day 14): */#p < 0.05; **/##p < 0.01; ***/###p < 0.001. e Number of mice with liver metastases compared with total number of mice and percentages (number in %)CC BY · PubMed Central
Fig. 3 REG exerts potent anti-angiogenic effects in orthotopic CT26 tumors. a Tumor vascularization analyzed by DCE-MRI. Longitudinal effects on vascularization are shown by relative amplitude changes versus baseline (day 4). b Representative images. Left panel: T1-weighted MR images with overlayed amplitude parameter maps derived from DCE-MRI analyses (scale bar indicates arbitrary units); right panel: IF staining for CD31 (green), VEGFR2 (red) and nuclei (DAPI; blue). Yellow staining indicates overlapping signal for CD31 and VEGFR2. Scale bar: 100 µm. c Effects on tumor vasculature analyzed by immunofluorescence (IF) on frozen tumor sections for CD31 and VEGFR2 and quantified: mean values ± SD (n = 5–7) and individual values (dots). Statistical significance (§day 7; #day 11; * day 14): */§/#p < 0.05; **/§§/##p < 0.01; ***/§§§/###p < 0.001; ****/§§§§/####p < 0.0001
Fig. 3 REG exerts potent anti-angiogenic effects in orthotopic CT26 tumors. a Tumor vascularization analyzed by DCE-MRI. Longitudinal effects on vascularization are shown by relative amplitude changes versus baseline (day 4). b Representative images. Left panel: T1-weighted MR images with overlayed amplitude parameter maps derived from DCE-MRI analyses (scale bar indicates arbitrary units); right panel: IF staining for CD31 (green), VEGFR2 (red) and nuclei (DAPI; blue). Yellow staining indicates overlapping signal for CD31 and VEGFR2. Scale bar: 100 µm. c Effects on tumor vasculature analyzed by immunofluorescence (IF) on frozen tumor sections for CD31 and VEGFR2 and quantified: mean values ± SD (n = 5–7) and individual values (dots). Statistical significance (§day 7; #day 11; * day 14): */§/#p < 0.05; **/§§/##p < 0.01; ***/§§§/###p < 0.001; ****/§§§§/####p < 0.0001CC BY · PubMed Central
Fig. 4 REG and REG + aPD1 significantly reduce intratumoral macrophages and Treg cells. a Staining of frozen tumor sections for macrophages (F4/80) and quantification: mean values ± SD (n = 5–7) and individual values (dots). b Representative immunofluorescence images. Left panel: staining for F4/80 in green; right panel: staining for FoxP3 in red. Nuclei are DAPI stained (blue). Scale bars: 100 µm. c Quantification of staining for Treg cells (FoxP3) on day 14 with mean values ± SD (n = 6–7) and individual values (dots) and ratio of CD8+ cytotoxic T cells to Treg cells (see Supplementary Figure S3a for quantification for CD8+). Statistical significance (§day 7; #day 11; * day 14): */§/#p < 0.05; **/§§/##p < 0.01; ***/§§§/###p < 0.001; ****/§§§§/####p < 0.0001
Fig. 4 REG and REG + aPD1 significantly reduce intratumoral macrophages and Treg cells. a Staining of frozen tumor sections for macrophages (F4/80) and quantification: mean values ± SD (n = 5–7) and individual values (dots). b Representative immunofluorescence images. Left panel: staining for F4/80 in green; right panel: staining for FoxP3 in red. Nuclei are DAPI stained (blue). Scale bars: 100 µm. c Quantification of staining for Treg cells (FoxP3) on day 14 with mean values ± SD (n = 6–7) and individual values (dots) and ratio of CD8+ cytotoxic T cells to Treg cells (see Supplementary Figure S3a for quantification for CD8+). Statistical significance (§day 7; #day 11; * day 14): */§/#p < 0.05; **/§§/##p < 0.01; ***/§§§/###p < 0.001; ****/§§§§/####p < 0.0001CC BY · PubMed Central
Fig. 5 Addition of aPD1 to REG leads to sustained inhibition of tumor growth and metastasis after discontinuation of therapy. a Study design. Gray arrowhead indicates imaging before first treatment for baseline determination. b Tumor growth curves, mean RTV given as a percentage of the baseline volumes ± SD (n = 7). Black arrow indicates treatment stop. Statistical significance: *p < 0.05; ***p < 0.001. c Representative images. Top panel: dissected tumors (arrow indicates tumor; * indicates cecum tissue); middle panel: T2-weighted MR images, white arrows indicate tumors; bottom panel: livers with metastases indicated by black arrows. Scale bar: 10 mm (MRI and ex vivo). d Number of mice with liver metastases vs total number of mice and percentages (number in %)
Fig. 5 Addition of aPD1 to REG leads to sustained inhibition of tumor growth and metastasis after discontinuation of therapy. a Study design. Gray arrowhead indicates imaging before first treatment for baseline determination. b Tumor growth curves, mean RTV given as a percentage of the baseline volumes ± SD (n = 7). Black arrow indicates treatment stop. Statistical significance: *p < 0.05; ***p < 0.001. c Representative images. Top panel: dissected tumors (arrow indicates tumor; * indicates cecum tissue); middle panel: T2-weighted MR images, white arrows indicate tumors; bottom panel: livers with metastases indicated by black arrows. Scale bar: 10 mm (MRI and ex vivo). d Number of mice with liver metastases vs total number of mice and percentages (number in %)CC BY · PubMed Central
Fig. 6 REG + aPD1 relieves the immunosuppressive tumor microenvironment and induces sustained suppression of tumor growth and metastasis. a Effects on tumor vasculature analyzed by DCE-MRI and CD31 staining. Longitudinal effects on vascularization are shown by relative amplitude changes versus baseline (day 4). Black arrow indicates treatment stop. b Effects on Treg cells. Quantification of immunostaining for FoxP3+ Treg cells and determination of the ratio of CD8+ cytotoxic T cells to Treg cells (see Supplementary Figure S4b for quantification of CD8+ cells). c Effects on macrophages and polarization. Quantification of total macrophages (F4/80), CD206 (M2) and iNOS (M1). Mean values ± SD (n = 6–7) and individual values (dots) are shown. *p < 0.05; **p < 0.01; ***p < 0.001. d Representative DCE-MRI and immunofluorescence images. Left panel: T1-weighted MR images with overlayed amplitude parameter maps from DCE-MRI analyses (scale bar indicates arbitrary units); panels 2–8: images of co-stainings as indicated by the antigen labels. Yellow staining indicates overlapping signals. Nuclei are DAPI stained (blue). Scale bars: 100 µm. e Mechanisms of sustained tumor growth inhibition by REG + aPD1. In untreated tumors, monocytes are recruited which differentiate to M2 macrophages. In addition, VEGFA promotes tumor angiogenesis, proliferation of Treg cells, and upregulation of PD1 on cytotoxic T cells. Together this creates an immunosuppressive tumor microenvironment that inhibits cytotoxic T cell activity, thus driving tumor growth and liver metastasis. Via inhibition of VEGFR and CSF1R signaling, REG reduces tumor vascularization and reduces the number of intratumoral macrophages and Treg cells. Blockade of PD1 by aPD1, which is likely enhanced by REG-mediated prevention of PD1 expression, leads to the activation of cytotoxic T cells, increases IFNγ expression, and induces tumor cell death. Importantly, REG and aPD1 synergize to induce sustained M1 polarization resulting in durable suppression of tumor growth and liver metastasis
Fig. 6 REG + aPD1 relieves the immunosuppressive tumor microenvironment and induces sustained suppression of tumor growth and metastasis. a Effects on tumor vasculature analyzed by DCE-MRI and CD31 staining. Longitudinal effects on vascularization are shown by relative amplitude changes versus baseline (day 4). Black arrow indicates treatment stop. b Effects on Treg cells. Quantification of immunostaining for FoxP3+ Treg cells and determination of the ratio of CD8+ cytotoxic T cells to Treg cells (see Supplementary Figure S4b for quantification of CD8+ cells). c Effects on macrophages and polarization. Quantification of total macrophages (F4/80), CD206 (M2) and iNOS (M1). Mean values ± SD (n = 6–7) and individual values (dots) are shown. *p < 0.05; **p < 0.01; ***p < 0.001. d Representative DCE-MRI and immunofluorescence images. Left panel: T1-weighted MR images with overlayed amplitude parameter maps from DCE-MRI analyses (scale bar indicates arbitrary units); panels 2–8: images of co-stainings as indicated by the antigen labels. Yellow staining indicates overlapping signals. Nuclei are DAPI stained (blue). Scale bars: 100 µm. e Mechanisms of sustained tumor growth inhibition by REG + aPD1. In untreated tumors, monocytes are recruited which differentiate to M2 macrophages. In addition, VEGFA promotes tumor angiogenesis, proliferation of Treg cells, and upregulation of PD1 on cytotoxic T cells. Together this creates an immunosuppressive tumor microenvironment that inhibits cytotoxic T cell activity, thus driving tumor growth and liver metastasis. Via inhibition of VEGFR and CSF1R signaling, REG reduces tumor vascularization and reduces the number of intratumoral macrophages and Treg cells. Blockade of PD1 by aPD1, which is likely enhanced by REG-mediated prevention of PD1 expression, leads to the activation of cytotoxic T cells, increases IFNγ expression, and induces tumor cell death. Importantly, REG and aPD1 synergize to induce sustained M1 polarization resulting in durable suppression of tumor growth and liver metastasisCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 114

Metadata

Authors
Doleschel, D., Hoff, S., Koletnik, S., Rix, A., Zopf, D., Kiessling, F., & Lederle, W.
Affiliations
  • RWTH Aachen University (DE)
  • Bayer (Germany) (DE)
  • Fraunhofer Institute for Digital Medicine (DE)
Corresponding author
  • Zopf, Dieter
  • Lederle, Wiltrud
Venue
Journal of Experimental & Clinical Cancer Research
Published
2021-09-13
Volume
40
Issue
1
Pages
288-288
ISSN
  • 0392-9078 (ISSN-L)
  • 1756-9966
OpenAlex
W3200675468
Cited by
114
References
50
Citations by year
2026: 14 · 2025: 26 · 2024: 23 · 2023: 33 · 2022: 17 · 2021: 1
FWCI
6.73
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Publikationsdatenbank der Fraunhofer-Gesellschaft (Fraunhofer-Gesellschaft) (submittedVersion, other-oa)
  • Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
  • Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion)
  • RWTH Publications (RWTH Aachen) (submittedVersion, other-oa)
  • RWTH Publications (RWTH Aachen)
Funders
  • Bayer
  • RWTH Aachen University
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
regorafenib, anti-PD-1 therapy, colorectal cancer, combination therapy, multikinase inhibitor, tumor microenvironment, tumor regrowth, liver metastasis, regulatory T cells, M1 macrophage polarization, interferon-gamma, immunosuppressive macrophages, microsatellite stable tumors, hypermutated tumors, drug synergy, dynamic contrast-enhanced MRI
MeSH terms
Animals, Drug Synergism, Humans, Immunotherapy, Phenylurea Compounds, Pyridines, Colorectal Neoplasms, Cell Line, Tumor, Mice, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. https://app.cochat.ai/papers/10.1186/s13046-021-02043-0
The paper
Doleschel, D., Hoff, S., Koletnik, S., Rix, A., Zopf, D., Kiessling, F., & Lederle, W. (2021). Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-021-02043-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.